secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024154
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Q3 net loss $29.1M; starts uUTI trial; cash into 2024
------------------------------------------------------------

- Net loss $29.1M vs income $3.7M YoY; non-GAAP net loss $5.3M.
- Cash, equivalents & short-term investments $64.3M; runway into 2024.
- R&D expense $4.4M (up from $1.8M) due to REASSURE trial startup.
- Enrollment in Phase 3 REASSURE trial for uUTI began Oct 2022; completion expected H1 2024.
- New US patent (No. 11,478,428) for oral sulopenem bilayer tablet extends protection to 2039.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017022024154/0000950170-22-024154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017022024154/itrm-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer